Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial
Masashi Mizokami(National Center for Global Health and Medicine), Osamu Yokosuka(Chiba University), Tetsuo Takehara(Osaka University), Naoya Sakamoto(Hokkaido University), Masaaki Korenaga(National Center for Global Health and Medicine), Hitoshi Mochizuki(Yamanashi Prefectural Central Hospital), Kunio Nakane(Akita University Hospital), Hirayuki Enomoto(Hyogo Medical University), Fusao Ikeda(Okayama University), Mikio Yanase(National Center for Global Health and Medicine), Hidenori Toyoda(Ogaki Municipal Hospital), Takuya Genda(Juntendo University Shizuoka Hospital), Takeji Umemura(Shinshu University), Hiroshi Yatsuhashi(Nagasaki Medical Center), Tatsuya Ide(Kurume University), Nobuo Toda(Mitsui Memorial Hospital), Kazushige Nirei(Nihon University), Yoshiyuki Ueno(Yamagata University Hospital), Yoichi Nishigaki(Gifu Municipal Hospital), Juan Betular(Gilead Sciences (United States)), Bing Gao(Gilead Sciences (United States)), Akinobu Ishizaki, Masa Omote, Hongmei Mo(Gilead Sciences (United States)), Kim Garrison(Gilead Sciences (United States)), Phillip S. Pang(Gilead Sciences (United States)), Steven Knox(Gilead Sciences (United States)), William T. Symonds(Gilead Sciences (United States)), John G. McHutchison(Gilead Sciences (United States)), Namiki Izumi(Musashino Red Cross Hospital), Masao Omata(Yamanashi Prefectural Central Hospital)
Cited by 362
Abstract
Related Papers
No related papers found
Powered by citation graph analysis